August 12, 2019

Seema Verma, MPH
Administrator
Centers for Medicare & Medicaid Services
Department of Health and Human Services
200 Independence Avenue, SW
Washington, DC 20201

RE: Request for comments on Medicare and Medicaid Programs; Risk Adjustment Data Validation [CMS-4185-N4]

Dear Ms. Verma:

The Medicare Payment Advisory Commission (MedPAC) welcomes the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS’s) “Medicare and Medicaid Programs; Risk Adjustment Data Validation” request for additional comment published in the Federal Register, vol. 84, no. 125, pages 30983 to 30984. We appreciate your staff’s work to implement the risk adjustment data validation (RADV) provisions and specifically to evaluate whether an adjustment for unsupported fee-for-service (FFS) diagnoses is needed. We commend the transparency of your staff’s careful consideration of the issues and the substantial release of additional data.

We submit the following comment in addition to our December 19, 2018, comment on the initial proposed rule [CMS-4185-P] addressing Medicare Advantage (MA) RADV provisions.¹

Request for public comment

The MA risk adjustment model uses FFS spending, demographic, and diagnostic data to calculate a set of risk adjustment coefficients that represent the relative amount of FFS spending related to different demographic factors and diagnoses. These factors are applied to MA enrollees’ demographic and diagnostic data to estimate a risk score—a standardized expected spending amount—that adjusts CMS’s payment to the plan. CMS tracks beneficiary demographic data, but MA plans submit diagnoses for their enrollees to CMS for risk adjustment. Because diagnoses are a major factor in determining plan payments, RADV audits are necessary for ensuring payment accuracy by verifying that diagnoses submitted by MA plans are documented in patients’ medical records. Through the audits, plans are held accountable for submitting diagnostic data that does not conform to program rules.

In a 2012 RADV audit methods memo, CMS stated that after calculating any overpayment recovery amount warranted by the RADV audits, the agency would apply an FFS adjuster to that amount to account “for the fact that the documentation standard used in RADV audits to determine a contract’s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).”2 The expectation may have been that MA improper payment estimates would decrease if the calculation of risk adjustment coefficients was based only on the FFS diagnoses with medical record support (rather than all FFS diagnoses). However, as part of the initial proposed rule addressing MA RADV provisions [CMS-4185-P], CMS released the results of its study demonstrating that unsupported FFS diagnoses introduce no systematic bias on MA risk scores and thus proposed not to apply an FFS adjuster. CMS subsequently duplicated the study and released results confirming the initial finding.3

The Secretary now requests additional public comment about whether statutory text related to risk adjustment for payments to MA plans mandates an FFS adjuster, prohibits an FFS adjuster, or otherwise informs the proposal not to apply an FFS adjuster in the RADV extrapolated audit methodology.4

Comment

Without weighing in on the legal question of the applicability of the statutory provision, we support CMS’s conclusion that an FFS adjuster is unwarranted in determining overpayment recovery amounts identified through RADV audits.

The Commission supports including private plans in the Medicare program because they allow beneficiaries to choose between FFS Medicare and alternative delivery systems that private plans can provide. Plans often have flexibility in payment methods, including the ability to negotiate with individual providers; care-management techniques that fill potential gaps in care delivery (e.g., programs focused on preventing avoidable hospital readmissions); and robust information systems that can potentially provide timely feedback to providers. Plans also can reward beneficiaries for seeking care from more efficient providers and give beneficiaries more predictable cost sharing; one trade-off is that plans typically restrict the choice of providers.

By contrast, traditional FFS Medicare has lower administrative costs and offers beneficiaries an unconstrained choice of health care providers, but it lacks incentives to coordinate care and is limited in its ability to modify care delivery. Because private plans and traditional FFS Medicare

---


4 The request for public comment cites 42 U.S.C. 1395w-23, in particular (a)(1)(c) “which requires risk adjustment in subclause (a)(1)(c)(i), mandates a downward adjustment of risk scores in subclause (a)(1)(c)(ii), and includes provisions about risk adjustment for special needs individuals with chronic health conditions in subclause (a)(1)(c)(iii).”
have structural aspects that appeal to different segments of the Medicare population, the Commission’s long-standing position is that the Medicare program should provide a financially neutral choice between private MA plans and traditional FFS Medicare. Medicare’s payment systems, as well as monitoring and enforcement efforts, should ensure parity between the two sectors and not unduly favor one component of the program over the other.

In assessing parity between FFS Medicare and MA, two diagnostic coding issues come into play. First, MA plans have a greater financial incentive than providers in FFS Medicare to report all diagnoses codes for their enrollees. For the past several years, we have reported on the impact of these financial incentives and on factors that lead to greater coding intensity in MA (e.g., the use of home health risk assessments, chart reviews, pay-for-coding programs, and electronic health records to improve data sharing and to remind providers to identify diagnoses). We estimate that such coding resulted in MA risk scores (and payments) that were on average 7 percent greater than comparable FFS beneficiaries in 2017 without a commensurate difference in the characteristics of the MA enrollee relative to an otherwise comparable FFS beneficiary. This excess coding results in payments to MA plans that are higher than warranted given the enrollees health status relative to comparable beneficiaries in FFS. The Congress has partially addressed this issue by mandating a coding intensity adjustment, and the Commission has recommended a set of policies that would more fully and equitably address the issue.

The second coding issue that has the potential to undermine financial parity between MA and FFS Medicare is the matter discussed in the current request for comment pertaining to medical record documentation requirements in MA and FFS. While CMS requires medical record documentation for diagnoses submitted by MA plans, it does not have a similar documentation requirement for diagnoses in FFS claims, which are the source of diagnostic information used to calculate risk adjustment coefficients in the MA payment system. If the FFS data used to calculate risk adjustment coefficients include diagnoses that are not documented in a patient’s medical record, use of those coefficients could introduce a bias into the system because the coefficients would be either greater or smaller than if the documentation requirement were applied equally to FFS and MA. This potential for bias has led some stakeholders to call for a counterbalancing adjustment, the FFS adjuster which is the subject of CMS’s current solicitation.

We believe a guiding principle for the risk adjustment system is that one set of risk coefficients should be used for all payments to MA plans (i.e., the same set of risk coefficients should determine monthly payment amounts for all MA plans and should be used to determine overpayment amounts through RADV audits). Applying one set of coefficients to determine monthly plan payment amounts and a different set of coefficients (or an FFS adjuster based on a different set of coefficients) to determine RADV overpayment amounts would introduce inconsistency in payments to plans and would undermine financial neutrality between FFS Medicare and MA. Therefore, we reiterate our comment from December 19, 2018, agreeing with CMS’s conclusion that if unsupported FFS diagnoses caused bias, the impact would affect all MA risk scores such that an appropriate remedy would require a modification to the entire risk

---

adjustment system, not an adjustment only for the contracts subject to RADV audits. An
adjustment only to MA contracts under RADV audits would fail to fully address the potential bias.

Although there is a potential for bias arising from differing documentation standards, CMS’s study shows that bias due to including undocumented FFS diagnoses is negligible (i.e., causing a less than 0.1 percent increase in MA risk scores in both iterations of the study). The negligible effect on MA risk scores is likely due to the fact that (1) the risk adjustment model attributes Medicare spending to the variables in the model so that all FFS spending is accounted for, and (2) the FFS and MA populations are substantially similar with regard to the distribution of risk adjustment coefficients.

Based on the results of CMS’s study, we conclude that CMS should not make an adjustment to the entire risk adjustment system. Implementing an adjustment to remove unsupported FFS diagnoses from the risk adjustment system in each year would require significant effort and would offer negligible benefit. Because MA risk scores using coefficients with and without unsupported FFS diagnoses are equivalent in aggregate, it is appropriate for the Secretary to require medical record documentation of MA diagnoses and enforce program rules through extrapolated RADV audits.

**Conclusion**

The Commission values the ongoing cooperation and collaboration between CMS and our staff on technical policy issues. We look forward to continuing this productive relationship. If you have any questions, or require clarification of our comments, please feel free to contact James E. Mathews, the Commission’s Executive Director, at 202-220-3700.

Sincerely,

Francis J. Crosson, M.D.
Chairman